US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Enliven Treateutics

20.22

+0.45002.28%

Post-market: 20.220.00000.00%18:46 EDT

Volume:346.79K

Turnover:6.97M

Market Cap:1.20B

PE:-10.11

High:20.79

Open:19.95

Low:19.63

Close:19.77

52wk High:30.03

52wk Low:13.30

Shares:59.23M

Float Shares:35.00M

Volume Ratio:0.98

T/O Rate:0.99%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.0009

EPS(LYR):-1.8912

ROE:-25.26%

ROA:-17.19%

PB:2.45

PE(LYR):-10.69

Loading ...

Overview Company News Filings

Enliven Therapeutics CEO Samuel Kintz Reports Disposal of Common Shares

CFO Benjamin Hohl Reports Disposal of Common Shares of Enliven Therapeutics Inc

Enliven Therapeutics Closes Public Offering

MT Newswires Live

Enliven Therapeutics Is Maintained at Outperform by Baird

Enliven price target raised to $52 from $40 at Baird

Enliven Therapeutics Files Prospectus for Public Offering of Common Stock and Pre-Funded Warrants

Promising Potential of Enliven Therapeutics’ ELVN-001: Buy Rating Reiterated with Strong Efficacy, Safety, and Market Opportunity

Optimistic Buy Rating for Enliven Therapeutics Driven by Promising ELVN-001 Data and Strategic Growth Plans

Enliven assigned with a Buy at Goldman Sachs

Enliven Therapeutics Up Over 16%, on Track for Largest Percent Increase Since April 2024 -- Data Talk

Enliven Therapeutics Inc. Announces $200 Million Public Offering of Common Stock and Pre-Funded Warrants

Enliven Therapeutics Announces Positive Phase 1 Trial Results for ELVN-001 in CML at EHA 2025 Congress

Enliven Therapeutics’ ELVN-001: Promising CML Treatment with Strong Safety Profile and Upcoming Phase 1b Trial Insights

COO Anish Patel Reports Disposal of Common Shares of Enliven Therapeutics Inc

Enliven Therapeutics CEO Samuel Kintz Reports Disposal of Common Shares

Enliven Therapeutics: Buy Rating Backed by Promising ELVN-001 Developments in CML Treatment

CFO Benjamin Hohl Reports Disposal of Common Shares of Enliven Therapeutics Inc

Enliven Therapeutics’ ELVN-001: Promising Efficacy and Safety in Late Line CML Market

Enliven Therapeutics Inc. to Participate in TD Cowen's 6th Annual Oncology Innovation Summit

Enliven Therapeutics CEO Samuel Kintz Reports Disposal of Common Shares

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ELVN/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ELVN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ELVN\",,,,,undefined,":{"symbol":"ELVN","market":"US","secType":"STK","nameCN":"Enliven Treateutics","latestPrice":20.22,"timestamp":1755288000000,"preClose":19.77,"halted":0,"volume":346790,"hourTrading":{"tag":"盘后","latestPrice":20.22,"preClose":20.22,"latestTime":"18:46 EDT","volume":8119,"amount":164166.48,"timestamp":1755298008353},"delay":0,"floatShares":34999600,"shares":59226171,"eps":-2.000917,"marketStatus":"Market Closed","change":0.45,"latestTime":"08-15 16:00:00 EDT","open":19.95,"high":20.785,"low":19.63,"amount":6974933.864340001,"amplitude":0.058422,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.000917,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1755504000000},"marketStatusCode":7,"adr":0,"listingDate":1583985600000,"exchange":"NASDAQ","adjPreClose":19.77,"preHourTrading":{"tag":"盘前","latestPrice":19.77,"preClose":19.77,"latestTime":"08:47 EDT","volume":21108,"amount":418561.50815999997,"timestamp":1755262079702},"postHourTrading":{"tag":"盘后","latestPrice":20.22,"preClose":20.22,"latestTime":"18:46 EDT","volume":8119,"amount":164166.48,"timestamp":1755298008353},"volumeRatio":0.9783023273301719,"impliedVol":0.481,"impliedVolPercentile":0.24},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ELVN\",,,,,undefined,":{"symbol":"ELVN","floatShares":34999600,"roa":"-17.19%","roe":"-25.26%","lyrEps":-1.891209,"volumeRatio":0.9783023273301719,"shares":59226171,"dividePrice":0,"high":20.785,"amplitude":0.058422,"preClose":19.77,"low":19.63,"week52Low":13.3,"pbRate":"2.45","week52High":30.03,"institutionHeld":0,"latestPrice":20.22,"eps":-2.000917,"divideRate":0,"volume":346790,"delay":0,"ttmEps":-2.000917,"open":19.95,"prevYearClose":22.5,"prevWeekClose":17.69,"prevMonthClose":18.81,"prevQuarterClose":20.06,"fiveDayClose":17.69,"twentyDayClose":22.66,"sixtyDayClose":17.38},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ELVN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-13","symbol":"ELVN","fiscalQuarterEnding":"2025/06","expectedEps":-0.53,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1755057600000,"reportTimeType":"post","actualEps":-0.49},{"market":"US","date":"2025-05-14","symbol":"ELVN","fiscalQuarterEnding":"2025/03","expectedEps":-0.51,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747195200000,"reportTimeType":"post","actualEps":-0.57},{"market":"US","date":"2025-03-13","symbol":"ELVN","fiscalQuarterEnding":"2024/12","expectedEps":-0.53,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1741838400000,"reportTimeType":"post","actualEps":-0.46},{"market":"US","date":"2024-11-13","symbol":"ELVN","fiscalQuarterEnding":"2024/09","expectedEps":-0.52,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"post","actualEps":-0.48},{"market":"US","date":"2024-08-13","symbol":"ELVN","fiscalQuarterEnding":"2024/06","expectedEps":-0.58,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723521600000,"reportTimeType":"post","actualEps":-0.41}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ELVN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ELVN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":9,"updateTime":1750132800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ELVN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ELVN","date":"2025-08-15","current":-11.683894,"percent":0.645378,"low":-26.682642,"twenty":-16.52193,"median":-12.73478,"eighty":-10.409257,"high":-6.665619,"avg":-13.612407,"sd":4.229421,"marketCap":1170901400},"quantilePoints":[{"date":"2023-02-24","current":-26.682642,"twenty":-26.682642,"median":-26.682642,"eighty":-26.682642,"marketCap":974023148},{"date":"2023-03-03","current":-24.8289,"twenty":-26.345598,"median":-24.559265,"eighty":-24.199752,"marketCap":906354172},{"date":"2023-03-10","current":-23.694186,"twenty":-25.199648,"median":-24.28963,"eighty":-23.806534,"marketCap":864932556},{"date":"2023-03-17","current":-24.997422,"twenty":-25.053596,"median":-24.508708,"eighty":-23.817768,"marketCap":912505897},{"date":"2023-03-24","current":-25.045524,"twenty":-25.045524,"median":-24.501056,"eighty":-23.817768,"marketCap":943264523},{"date":"2023-03-31","current":-23.847695,"twenty":-25.154418,"median":-24.513309,"eighty":-23.847695,"marketCap":898151871},{"date":"2023-04-06","current":-25.11086,"twenty":-25.119572,"median":-24.513309,"eighty":-23.847695,"marketCap":945725213},{"date":"2023-04-14","current":-20.962015,"twenty":-25.076502,"median":-24.390743,"eighty":-23.811629,"marketCap":789471394},{"date":"2023-04-21","current":-21.332253,"twenty":-25.048753,"median":-24.119928,"eighty":-22.848051,"marketCap":803415304},{"date":"2023-04-28","current":-20.635334,"twenty":-25.016663,"median":-23.926845,"eighty":-21.458569,"marketCap":777167943},{"date":"2023-05-05","current":-20.341321,"twenty":-24.896309,"median":-23.847695,"eighty":-21.260383,"marketCap":766094838},{"date":"2023-05-12","current":-20.851059,"twenty":-24.795534,"median":-23.81078,"eighty":-20.994683,"marketCap":785292584},{"date":"2023-05-19","current":-21.89907,"twenty":-24.705543,"median":-23.593073,"eighty":-21.113722,"marketCap":824762787},{"date":"2023-05-26","current":-21.462399,"twenty":-24.613192,"median":-22.720646,"eighty":-21.211975,"marketCap":808316869},{"date":"2023-06-02","current":-18.734285,"twenty":-24.559265,"median":-21.980633,"eighty":-20.954392,"marketCap":819006716},{"date":"2023-06-09","current":-21.377022,"twenty":-24.515759,"median":-21.83357,"eighty":-20.954392,"marketCap":934539290},{"date":"2023-06-16","current":-18.254642,"twenty":-24.497376,"median":-21.673899,"eighty":-20.758384,"marketCap":798038170},{"date":"2023-06-23","current":-20.812737,"twenty":-24.451411,"median":-21.642525,"eighty":-20.734427,"marketCap":909870413},{"date":"2023-06-30","current":-18.32988,"twenty":-24.28963,"median":-21.616844,"eighty":-20.341321,"marketCap":801327354},{"date":"2023-07-07","current":-17.361189,"twenty":-24.217728,"median":-21.517191,"eighty":-20.09872,"marketCap":758979115},{"date":"2023-07-14","current":-17.135475,"twenty":-24.135893,"median":-21.462399,"eighty":-19.332427,"marketCap":749111564},{"date":"2023-07-21","current":-17.972499,"twenty":-24.119928,"median":-21.435107,"eighty":-18.517975,"marketCap":785703732},{"date":"2023-07-28","current":-16.984999,"twenty":-23.971833,"median":-21.377022,"eighty":-18.220785,"marketCap":742533197},{"date":"2023-08-04","current":-16.881547,"twenty":-23.922067,"median":-21.256028,"eighty":-17.820142,"marketCap":738010570},{"date":"2023-08-11","current":-16.491696,"twenty":-23.861932,"median":-21.016461,"eighty":-17.568094,"marketCap":720967464},{"date":"2023-08-18","current":-12.980214,"twenty":-23.847695,"median":-20.922018,"eighty":-17.248332,"marketCap":669117064},{"date":"2023-08-25","current":-13.578933,"twenty":-23.823753,"median":-20.812737,"eighty":-17.129832,"marketCap":699980398},{"date":"2023-09-01","current":-12.469308,"twenty":-23.815574,"median":-20.736061,"eighty":-17.000046,"marketCap":642780353},{"date":"2023-09-08","current":-12.908368,"twenty":-23.809931,"median":-20.564155,"eighty":-16.862737,"marketCap":665413464},{"date":"2023-09-15","current":-13.123907,"twenty":-23.739125,"median":-20.333094,"eighty":-16.776213,"marketCap":676524264},{"date":"2023-09-22","current":-10.154264,"twenty":-23.633518,"median":-19.996164,"eighty":-15.495828,"marketCap":523442131},{"date":"2023-09-29","current":-10.968521,"twenty":-23.474031,"median":-19.373808,"eighty":-13.527842,"marketCap":565416265},{"date":"2023-10-06","current":-11.511359,"twenty":-23.372472,"median":-19.044642,"eighty":-13.224491,"marketCap":593399020},{"date":"2023-10-13","current":-9.994605,"twenty":-22.593241,"median":-18.52738,"eighty":-13.107941,"marketCap":515211909},{"date":"2023-10-20","current":-10.130315,"twenty":-22.058041,"median":-18.391011,"eighty":-12.999373,"marketCap":522207598},{"date":"2023-10-27","current":-9.555545,"twenty":-22.040989,"median":-18.292261,"eighty":-12.964248,"marketCap":492578798},{"date":"2023-11-03","current":-9.731169,"twenty":-21.920278,"median":-17.972499,"eighty":-12.485274,"marketCap":501632043},{"date":"2023-11-10","current":-7.695346,"twenty":-21.89907,"median":-17.817321,"eighty":-12.245786,"marketCap":475295332},{"date":"2023-11-17","current":-6.952736,"twenty":-21.83357,"median":-17.803213,"eighty":-11.215991,"marketCap":429428758},{"date":"2023-11-24","current":-7.786797,"twenty":-21.720035,"median":-17.492856,"eighty":-10.958941,"marketCap":480943724},{"date":"2023-12-01","current":-7.513225,"twenty":-21.68071,"median":-17.309463,"eighty":-10.760965,"marketCap":464046815},{"date":"2023-12-08","current":-7.506552,"twenty":-21.671453,"median":-17.210713,"eighty":-10.505512,"marketCap":463634696},{"date":"2023-12-15","current":-7.893557,"twenty":-21.652352,"median":-17.121368,"eighty":-10.333081,"marketCap":487537640},{"date":"2023-12-22","current":-8.620858,"twenty":-21.63925,"median":-17.013213,"eighty":-10.031327,"marketCap":532458691},{"date":"2023-12-29","current":-9.721819,"twenty":-21.630859,"median":-16.994403,"eighty":-9.985025,"marketCap":600458446},{"date":"2024-01-05","current":-9.735164,"twenty":-21.621546,"median":-16.919166,"eighty":-9.908649,"marketCap":601282686},{"date":"2024-01-12","current":-7.653347,"twenty":-21.612141,"median":-16.825118,"eighty":-9.735164,"marketCap":472701330},{"date":"2024-01-19","current":-8.547461,"twenty":-21.544748,"median":-16.787499,"eighty":-9.657763,"marketCap":527925374},{"date":"2024-01-26","current":-10.90285,"twenty":-21.510766,"median":-16.702856,"eighty":-9.657763,"marketCap":673403638},{"date":"2024-02-02","current":-10.972911,"twenty":-21.471637,"median":-15.246862,"eighty":-9.711143,"marketCap":677730895},{"date":"2024-02-09","current":-10.282309,"twenty":-21.462504,"median":-13.618847,"eighty":-9.729299,"marketCap":635076503},{"date":"2024-02-16","current":-11.543409,"twenty":-21.454109,"median":-13.399317,"eighty":-9.734365,"marketCap":712967132},{"date":"2024-02-23","current":-10.609261,"twenty":-21.445153,"median":-13.291548,"eighty":-9.761506,"marketCap":655270370},{"date":"2024-03-01","current":-10.655968,"twenty":-21.434015,"median":-13.147855,"eighty":-9.803015,"marketCap":658155208},{"date":"2024-03-08","current":-10.275636,"twenty":-21.409359,"median":-13.10395,"eighty":-9.82474,"marketCap":634664384},{"date":"2024-03-15","current":-6.665619,"twenty":-21.384546,"median":-13.044078,"eighty":-9.733566,"marketCap":477151673},{"date":"2024-03-22","current":-10.431636,"twenty":-21.350161,"median":-12.972231,"eighty":-9.727429,"marketCap":746738233},{"date":"2024-03-28","current":-10.760874,"twenty":-21.310474,"median":-12.880428,"eighty":-9.732767,"marketCap":770306384},{"date":"2024-04-05","current":-12.135517,"twenty":-21.260383,"median":-12.485274,"eighty":-9.752725,"marketCap":868708833},{"date":"2024-04-12","current":-15.541291,"twenty":-21.211975,"median":-12.53879,"eighty":-9.795033,"marketCap":1112507764},{"date":"2024-04-19","current":-11.553574,"twenty":-21.113722,"median":-12.520461,"eighty":-9.82282,"marketCap":827051011},{"date":"2024-04-26","current":-10.971645,"twenty":-20.994683,"median":-12.453342,"eighty":-9.833917,"marketCap":785394226},{"date":"2024-05-03","current":-13.724364,"twenty":-20.956933,"median":-12.42141,"eighty":-9.861485,"marketCap":982444863},{"date":"2024-05-10","current":-15.627075,"twenty":-20.927476,"median":-12.477291,"eighty":-9.897956,"marketCap":1118648510},{"date":"2024-05-17","current":-14.069999,"twenty":-20.877259,"median":-12.55712,"eighty":-9.908649,"marketCap":1119943779},{"date":"2024-05-24","current":-13.579529,"twenty":-20.83573,"median":-12.880428,"eighty":-9.913987,"marketCap":1080903320},{"date":"2024-05-31","current":-13.31952,"twenty":-20.807747,"median":-12.919935,"eighty":-9.925997,"marketCap":1060207172},{"date":"2024-06-07","current":-11.936748,"twenty":-20.777985,"median":-12.852488,"eighty":-9.949337,"marketCap":950141299},{"date":"2024-06-14","current":-13.012238,"twenty":-20.738783,"median":-12.908368,"eighty":-9.978639,"marketCap":1035748089},{"date":"2024-06-21","current":-12.433128,"twenty":-20.734427,"median":-12.823141,"eighty":-9.991412,"marketCap":989652125},{"date":"2024-06-28","current":-13.857265,"twenty":-20.713737,"median":-12.852488,"eighty":-9.999395,"marketCap":1103010568},{"date":"2024-07-05","current":-12.734501,"twenty":-20.635334,"median":-12.852488,"eighty":-10.018554,"marketCap":1013640841},{"date":"2024-07-12","current":-14.217731,"twenty":-20.492975,"median":-12.947875,"eighty":-10.03452,"marketCap":1131702953},{"date":"2024-07-15","current":-14.619562,"twenty":-20.462644,"median":-12.964248,"eighty":-10.034701,"marketCap":1163687908},{"date":"2024-08-02","current":-14.595925,"twenty":-20.432313,"median":-12.972231,"eighty":-10.034882,"marketCap":1161806440},{"date":"2024-08-09","current":-12.834959,"twenty":-20.33803,"median":-12.964248,"eighty":-10.054109,"marketCap":1021637080},{"date":"2024-08-16","current":-13.556309,"twenty":-20.306761,"median":-12.945278,"eighty":-10.088634,"marketCap":1122828410},{"date":"2024-08-23","current":-13.060138,"twenty":-20.227193,"median":-12.964248,"eighty":-10.111156,"marketCap":1081732040},{"date":"2024-08-30","current":-12.672326,"twenty":-20.030349,"median":-12.961651,"eighty":-10.130701,"marketCap":1049610739},{"date":"2024-09-06","current":-12.495529,"twenty":-19.786892,"median":-12.919935,"eighty":-10.135876,"marketCap":1034967205},{"date":"2024-09-13","current":-12.73506,"twenty":-19.581572,"median":-12.931502,"eighty":-10.154517,"marketCap":1054806832},{"date":"2024-09-20","current":-13.157091,"twenty":-19.368165,"median":-12.8873,"eighty":-10.156457,"marketCap":1089762365},{"date":"2024-09-27","current":-13.755918,"twenty":-19.332427,"median":-12.959054,"eighty":-10.16247,"marketCap":1139361432},{"date":"2024-10-04","current":-14.548651,"twenty":-19.185713,"median":-12.995005,"eighty":-10.191351,"marketCap":1205021150},{"date":"2024-10-11","current":-15.381306,"twenty":-18.794475,"median":-13.012238,"eighty":-10.271051,"marketCap":1273987472},{"date":"2024-10-18","current":-15.980134,"twenty":-18.692904,"median":-13.06278,"eighty":-10.276971,"marketCap":1323586540},{"date":"2024-10-25","current":-16.527633,"twenty":-18.517975,"median":-13.077247,"eighty":-10.282309,"marketCap":1368934258},{"date":"2024-10-31","current":-16.191149,"twenty":-18.480356,"median":-13.117169,"eighty":-10.282309,"marketCap":1341064306},{"date":"2024-11-08","current":-16.539039,"twenty":-18.452142,"median":-13.127899,"eighty":-10.308998,"marketCap":1369879003},{"date":"2024-11-15","current":-14.288385,"twenty":-18.32988,"median":-13.147855,"eighty":-10.377785,"marketCap":1217570416},{"date":"2024-11-22","current":-14.569336,"twenty":-18.254642,"median":-13.191309,"eighty":-10.377785,"marketCap":1241511408},{"date":"2024-11-29","current":-13.978765,"twenty":-18.119213,"median":-13.257473,"eighty":-10.420866,"marketCap":1191186467},{"date":"2024-12-06","current":-13.330857,"twenty":-17.99507,"median":-13.275582,"eighty":-10.465191,"marketCap":1135975609},{"date":"2024-12-13","current":-13.187514,"twenty":-17.927356,"median":-13.313517,"eighty":-10.47358,"marketCap":1123760818},{"date":"2024-12-20","current":-13.112976,"twenty":-17.840832,"median":-13.307514,"eighty":-10.475365,"marketCap":1117409126},{"date":"2024-12-27","current":-13.021237,"twenty":-17.81638,"median":-13.27352,"eighty":-10.487821,"marketCap":1109591659},{"date":"2025-01-03","current":-13.703547,"twenty":-17.808856,"median":-13.27352,"eighty":-10.502895,"marketCap":1167734067},{"date":"2025-01-10","current":-13.84689,"twenty":-17.803213,"median":-13.275582,"eighty":-10.521478,"marketCap":1179948858},{"date":"2025-01-17","current":-12.60841,"twenty":-17.759951,"median":-13.27352,"eighty":-10.564579,"marketCap":1074413060},{"date":"2025-01-24","current":-12.637079,"twenty":-17.586904,"median":-13.268745,"eighty":-10.609261,"marketCap":1076856018},{"date":"2025-01-31","current":-12.195584,"twenty":-17.492856,"median":-13.225528,"eighty":-10.642623,"marketCap":1039234460},{"date":"2025-02-07","current":-12.883628,"twenty":-17.445832,"median":-13.157091,"eighty":-10.649204,"marketCap":1097865460},{"date":"2025-02-14","current":-12.327459,"twenty":-17.361189,"median":-13.147855,"eighty":-10.655968,"marketCap":1050472069},{"date":"2025-02-21","current":-12.310258,"twenty":-17.278427,"median":-13.123907,"eighty":-10.661306,"marketCap":1049006294},{"date":"2025-02-28","current":-11.553409,"twenty":-17.220118,"median":-13.115073,"eighty":-10.671914,"marketCap":984512194},{"date":"2025-03-07","current":-12.304524,"twenty":-17.210713,"median":-13.077247,"eighty":-10.692528,"marketCap":1048517702},{"date":"2025-03-14","current":-11.168896,"twenty":-17.203189,"median":-13.06278,"eighty":-10.70156,"marketCap":994299783},{"date":"2025-03-21","current":-11.515688,"twenty":-17.148642,"median":-13.044078,"eighty":-10.73075,"marketCap":1025172571},{"date":"2025-03-28","current":-11.840461,"twenty":-17.112904,"median":-13.012192,"eighty":-10.756253,"marketCap":1054085181},{"date":"2025-04-04","current":-11.025775,"twenty":-17.062118,"median":-12.992568,"eighty":-10.756253,"marketCap":981558632},{"date":"2025-04-11","current":-8.207404,"twenty":-17.020737,"median":-12.961651,"eighty":-10.671914,"marketCap":730655976},{"date":"2025-04-17","current":-8.845942,"twenty":-17.00757,"median":-12.919935,"eighty":-10.646572,"marketCap":787501109},{"date":"2025-04-25","current":-10.073474,"twenty":-16.992523,"median":-12.900829,"eighty":-10.506428,"marketCap":896780977},{"date":"2025-05-02","current":-10.926692,"twenty":-16.945499,"median":-12.87493,"eighty":-10.47358,"marketCap":972737836},{"date":"2025-05-09","current":-10.268015,"twenty":-16.896595,"median":-12.837758,"eighty":-10.456802,"marketCap":914099729},{"date":"2025-05-16","current":-9.22086,"twenty":-16.864245,"median":-12.824716,"eighty":-10.419165,"marketCap":874414177},{"date":"2025-05-23","current":-8.677544,"twenty":-16.841798,"median":-12.774982,"eighty":-10.35027,"marketCap":822891456},{"date":"2025-05-30","current":-9.179465,"twenty":-16.826999,"median":-12.740411,"eighty":-10.284647,"marketCap":870488636},{"date":"2025-06-06","current":-11.057788,"twenty":-16.804427,"median":-12.734501,"eighty":-10.282309,"marketCap":1048610043},{"date":"2025-06-13","current":-10.172958,"twenty":-16.787499,"median":-12.717951,"eighty":-10.278305,"marketCap":964701612},{"date":"2025-06-20","current":-13.417901,"twenty":-16.781856,"median":-12.734501,"eighty":-10.282309,"marketCap":1272419584},{"date":"2025-06-27","current":-13.386798,"twenty":-16.747999,"median":-12.73478,"eighty":-10.283478,"marketCap":1269470072},{"date":"2025-07-03","current":-12.895368,"twenty":-16.702856,"median":-12.73478,"eighty":-10.288155,"marketCap":1222867778},{"date":"2025-07-11","current":-14.170598,"twenty":-16.684047,"median":-12.73506,"eighty":-10.29197,"marketCap":1343797781},{"date":"2025-07-18","current":-14.518953,"twenty":-16.539039,"median":-12.769279,"eighty":-10.308998,"marketCap":1376832318},{"date":"2025-07-25","current":-13.654285,"twenty":-16.539039,"median":-12.823141,"eighty":-10.377785,"marketCap":1294835877},{"date":"2025-08-01","current":-11.701007,"twenty":-16.527633,"median":-12.814277,"eighty":-10.377785,"marketCap":1109606508},{"date":"2025-08-08","current":-11.13493,"twenty":-16.527633,"median":-12.763576,"eighty":-10.392743,"marketCap":1055925385},{"date":"2025-08-15","current":-11.683894,"twenty":-16.52193,"median":-12.73478,"eighty":-10.409257,"marketCap":1170901400}],"updateTime":1755422877008},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ELVN\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2544185195","title":"Enliven Therapeutics CEO Samuel Kintz Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2544185195","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544185195?lang=en_us&edition=fundamental","pubTime":"2025-06-19 06:23","pubTimestamp":1750285398,"startTime":"0","endTime":"0","summary":"Samuel Kintz, President and CEO of Enliven Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 18, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250618:nNDL7TXPGz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Enliven Therapeutics CEO Samuel Kintz Reports Disposal of Common Shares","news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELVN","BK4007"],"gpt_icon":0},{"id":"2544918316","title":"CFO Benjamin Hohl Reports Disposal of Common Shares of Enliven Therapeutics Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2544918316","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544918316?lang=en_us&edition=fundamental","pubTime":"2025-06-18 04:24","pubTimestamp":1750191884,"startTime":"0","endTime":"0","summary":"Benjamin Hohl, Chief Financial Officer of Enliven Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 17, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250617:nNDL7CwZB9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"CFO Benjamin Hohl Reports Disposal of Common Shares of Enliven Therapeutics Inc","news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ELVN"],"gpt_icon":0},{"id":"2544706983","title":"Enliven Therapeutics Closes Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2544706983","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544706983?lang=en_us&edition=fundamental","pubTime":"2025-06-17 05:12","pubTimestamp":1750108344,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics (ELVN) said late Monday it has closed its public offering of shares and pre-funded warrants, raising about $230 million for the clinical-stage drugmaker.The closing includes the full exercise of its over-allotment option, according to the company.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","LENZ","ELVN","BK4539","BK4007"],"gpt_icon":0},{"id":"2543360869","title":"Enliven Therapeutics Is Maintained at Outperform by Baird","url":"https://stock-news.laohu8.com/highlight/detail?id=2543360869","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543360869?lang=en_us&edition=fundamental","pubTime":"2025-06-16 21:29","pubTimestamp":1750080540,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ELVN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 16, 2025 09:29 ET (13:29 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","ELVN"],"gpt_icon":0},{"id":"2543670670","title":"Enliven price target raised to $52 from $40 at Baird","url":"https://stock-news.laohu8.com/highlight/detail?id=2543670670","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543670670?lang=en_us&edition=fundamental","pubTime":"2025-06-16 20:50","pubTimestamp":1750078244,"startTime":"0","endTime":"0","summary":"Baird analyst Colleen Kusy raised the firm’s price target on Enliven (ELVN) to $52 from $40 and keeps an Outperform rating on the shares. The firm ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/enliven-price-target-raised-to-52-from-40-at-baird-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/enliven-price-target-raised-to-52-from-40-at-baird-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ELVN"],"gpt_icon":0},{"id":"2543679348","title":"Enliven Therapeutics Files Prospectus for Public Offering of Common Stock and Pre-Funded Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2543679348","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543679348?lang=en_us&edition=fundamental","pubTime":"2025-06-16 18:45","pubTimestamp":1750070701,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics Inc., a clinical-stage biopharmaceutical company, has announced the pricing of its public offering involving common stock and pre-funded warrants. The Boulder, Colorado-based company is offering 8,394,737 shares of common stock at $19.66 per share, alongside pre-funded warrants for 1,780,263 shares at $19.659 each. The expected gross proceeds from this offering are approximately $200 million, pending customary closing conditions anticipated by June 16, 2025. Additionally, Enliven has granted a 30-day option to the underwriters to purchase an extra 1,526,250 shares. The offering is conducted under a Registration Statement on Form S-3 filed with the SEC, with Jefferies, Goldman Sachs & Co. LLC, TD Cowen, and Mizuho serving as joint book-running managers.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250616:nNDL9kG2fQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1894683348.USD","LU2237443465.HKD","LU2237443549.SGD","LU2237443895.HKD","LU1868837136.USD","LU1894683264.USD","LU0106831901.USD","IE00BFXG1179.USD","LU1868836757.USD","LU1868837300.USD","LU0061475181.USD","BK4516","BK4552","LU0048573561.USD","LU0251142724.SGD","LU2237443382.USD","BK4127","LU1668664300.SGD","LU1868836591.USD","BK4533","BK4585","LU2471134523.USD","ELVN","BK4504","IE00B19Z3581.USD","IE00BSNM7G36.USD","LU2471134952.CNY","BK4550","IE0002270589.USD","LU2750360997.AUD","BK4588","LU2237438978.USD","LU0251131958.USD","LU2471134796.USD","LU2471134879.HKD","LU2237443978.SGD","LU2750360641.GBP","LU0742534661.SGD","IE0034235188.USD","LU1791807156.HKD","BK4007","LU0096364046.USD","LU2237443622.USD","IE00B19Z3B42.SGD","LU1868836914.USD","IE0004091025.USD","IE0004086264.USD"],"gpt_icon":0},{"id":"2543675658","title":"Promising Potential of Enliven Therapeutics’ ELVN-001: Buy Rating Reiterated with Strong Efficacy, Safety, and Market Opportunity","url":"https://stock-news.laohu8.com/highlight/detail?id=2543675658","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543675658?lang=en_us&edition=fundamental","pubTime":"2025-06-16 17:46","pubTimestamp":1750067175,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Justin Zelin from BTIG reiterated a Buy rating on Enliven Therapeutics (ELVN – Research Report), with a price targe...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-potential-of-enliven-therapeutics-elvn-001-buy-rating-reiterated-with-strong-efficacy-safety-and-market-opportunity-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-potential-of-enliven-therapeutics-elvn-001-buy-rating-reiterated-with-strong-efficacy-safety-and-market-opportunity-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","ELVN"],"gpt_icon":0},{"id":"2543627086","title":"Optimistic Buy Rating for Enliven Therapeutics Driven by Promising ELVN-001 Data and Strategic Growth Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2543627086","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543627086?lang=en_us&edition=fundamental","pubTime":"2025-06-16 17:16","pubTimestamp":1750065415,"startTime":"0","endTime":"0","summary":"Goldman Sachs analyst Salveen Richter has maintained their bullish stance on ELVN stock, giving a Buy rating on June 14. Salveen Richter has given ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/optimistic-buy-rating-for-enliven-therapeutics-driven-by-promising-elvn-001-data-and-strategic-growth-plans-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/optimistic-buy-rating-for-enliven-therapeutics-driven-by-promising-elvn-001-data-and-strategic-growth-plans-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","ELVN"],"gpt_icon":0},{"id":"2543627703","title":"Enliven assigned with a Buy at Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2543627703","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543627703?lang=en_us&edition=fundamental","pubTime":"2025-06-16 17:10","pubTimestamp":1750065005,"startTime":"0","endTime":"0","summary":"Goldman Sachs analyst Salveen Richter assigned of Enliven (ELVN) with a Buy rating and $37 price target from a previous Early-Stage Biotech designa...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/enliven-assigned-with-a-buy-at-goldman-sachs-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/enliven-assigned-with-a-buy-at-goldman-sachs-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1791807156.HKD","LU2237443549.SGD","IE00BSNM7G36.USD","LU0742534661.SGD","LU1894683264.USD","BK4585","LU1868836914.USD","LU2237438978.USD","LU0048573561.USD","BK4588","BK4552","LU0106831901.USD","LU1894683348.USD","LU2237443895.HKD","BK4127","BK4504","IE0004091025.USD","LU0061475181.USD","LU1868836591.USD","LU2471134796.USD","LU2471134879.HKD","LU2237443382.USD","LU1868836757.USD","IE00BFXG1179.USD","LU1868837300.USD","LU2471134523.USD","LU2750360997.AUD","LU2237443978.SGD","BK4550","LU2237443465.HKD","LU0096364046.USD","BK4533","LU0251131958.USD","LU2750360641.GBP","IE00B19Z3B42.SGD","LU1668664300.SGD","LU1868837136.USD","IE0002270589.USD","LU2237443622.USD","BK4516","IE0034235188.USD","IE0004086264.USD","LU0251142724.SGD","LU2471134952.CNY","ELVN","IE00B19Z3581.USD","BK4007"],"gpt_icon":0},{"id":"2543634396","title":"Enliven Therapeutics Up Over 16%, on Track for Largest Percent Increase Since April 2024 -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2543634396","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543634396?lang=en_us&edition=fundamental","pubTime":"2025-06-14 02:24","pubTimestamp":1749839040,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics, Inc.  is currently at $22.89, up $3.23 or 16.43%. --Would be highest close since Jan. 8, 2025, when it closed at $24.15. --On pace for largest percent increase since April 11, 2024, when it rose 20.18%. --Currently up two consecutive days; up 16.76% over this period. --Down 89.57% from its all-time closing high of $219.48 on June 11, 2020. --Up 5.48% from 52 weeks ago , when it closed at $21.70. --Up 53.52% from its 52-week closing low of $14.91 on April 10, 2025. --Traded as high as $23.49; highest intraday level since Jan. 10, 2025, when it hit $24.21. --Up 19.48% at today's intraday high; largest intraday percent increase since April 11, 2024, when it rose as much as 31.18%","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELVN","BK4007","BK4539","BK4139","LENZ"],"gpt_icon":0},{"id":"2543683294","title":"Enliven Therapeutics Inc. Announces $200 Million Public Offering of Common Stock and Pre-Funded Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2543683294","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543683294?lang=en_us&edition=fundamental","pubTime":"2025-06-13 18:11","pubTimestamp":1749809478,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics Inc., a clinical-stage biopharmaceutical company, has announced the commencement of an underwritten public offering valued at $200 million. The offering includes shares of its common stock and pre-funded warrants for those investors opting for them instead of the common stock. Additionally, Enliven may grant underwriters a 30-day option to purchase up to an extra $30 million in common stock. The offering is contingent on market conditions, with no assurance of completion or specific terms. Jefferies, Goldman Sachs & Co. LLC, TD Cowen, and Mizuho are serving as joint book-running managers, and LifeSci Capital is acting as lead manager for the offering.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeut","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250613:nNDL8fx953:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237443549.SGD","LU2471134952.CNY","LU1791807156.HKD","IE00BFXG1179.USD","LU2471134523.USD","LU1868836914.USD","LU0061475181.USD","BK4504","IE0004091025.USD","LU1868837300.USD","LU0251131958.USD","IE00B19Z3B42.SGD","IE0002270589.USD","LU0048573561.USD","LU1894683348.USD","IE0034235188.USD","LU2471134796.USD","LU2471134879.HKD","ELVN","LU2750360641.GBP","LU2237443382.USD","BK4552","BK4516","BK4127","LU2237443895.HKD","BK4550","LU0096364046.USD","BK4533","IE00BSNM7G36.USD","LU1868837136.USD","LU2237443622.USD","LU0106831901.USD","LU1868836757.USD","BK4007","LU2237438978.USD","LU2750360997.AUD","BK4585","LU0742534661.SGD","IE00B19Z3581.USD","LU2237443465.HKD","LU2237443978.SGD","LU1894683264.USD","LU0251142724.SGD","LU1868836591.USD","LU1668664300.SGD","IE0004086264.USD","BK4588"],"gpt_icon":0},{"id":"2543688000","title":"Enliven Therapeutics Announces Positive Phase 1 Trial Results for ELVN-001 in CML at EHA 2025 Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2543688000","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543688000?lang=en_us&edition=fundamental","pubTime":"2025-06-13 18:03","pubTimestamp":1749809004,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in small molecule therapeutics, announced updated positive results from their Phase 1 ENABLE clinical trial of ELVN-001 for chronic myeloid leukemia . The data was presented at the European Hematology Association  2025 Congress, taking place from June 12-15 in Milan, Italy, and virtually. The trial reported a cumulative major molecular response  rate of 47% by 24 weeks, with a favorable safety and tolerability profile across all dose levels. Enliven plans to initiate a Phase 3 pivotal trial in 2026, aiming to position ELVN-001 as a competitive treatment option in the CML landscape. Enliven will discuss these findings during a webcast and conference call on June 13, 2025, at 1:30 p.m. ET.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purp","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250613:nNDL9dn6BH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELVN","BK4007"],"gpt_icon":0},{"id":"2543549929","title":"Enliven Therapeutics’ ELVN-001: Promising CML Treatment with Strong Safety Profile and Upcoming Phase 1b Trial Insights","url":"https://stock-news.laohu8.com/highlight/detail?id=2543549929","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543549929?lang=en_us&edition=fundamental","pubTime":"2025-06-13 00:45","pubTimestamp":1749746713,"startTime":"0","endTime":"0","summary":"JonesTrading analyst Soumit Roy has maintained their bullish stance on ELVN stock, giving a Buy rating on May 29. Soumit Roy has given his Buy rati...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/enliven-therapeutics-elvn-001-promising-cml-treatment-with-strong-safety-profile-and-upcoming-phase-1b-trial-insights-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/enliven-therapeutics-elvn-001-promising-cml-treatment-with-strong-safety-profile-and-upcoming-phase-1b-trial-insights-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","LENZ","ELVN","BK4139","BK4007"],"gpt_icon":0},{"id":"2542558764","title":"COO Anish Patel Reports Disposal of Common Shares of Enliven Therapeutics Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2542558764","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542558764?lang=en_us&edition=fundamental","pubTime":"2025-06-12 06:25","pubTimestamp":1749680758,"startTime":"0","endTime":"0","summary":"Anish Patel, Chief Operating Officer of Enliven Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 11, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250611:nNDLW9N67:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"COO Anish Patel Reports Disposal of Common Shares of Enliven Therapeutics Inc","news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ELVN"],"gpt_icon":0},{"id":"2541000610","title":"Enliven Therapeutics CEO Samuel Kintz Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2541000610","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541000610?lang=en_us&edition=fundamental","pubTime":"2025-06-06 04:54","pubTimestamp":1749156868,"startTime":"0","endTime":"0","summary":"Samuel Kintz, President and CEO of Enliven Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 05, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nNDL6ChjrF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Enliven Therapeutics CEO Samuel Kintz Reports Disposal of Common Shares","news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELVN","BK4007"],"gpt_icon":0},{"id":"2540970983","title":"Enliven Therapeutics: Buy Rating Backed by Promising ELVN-001 Developments in CML Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2540970983","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540970983?lang=en_us&edition=fundamental","pubTime":"2025-06-04 01:35","pubTimestamp":1748972112,"startTime":"0","endTime":"0","summary":"JonesTrading analyst Soumit Roy has maintained their bullish stance on ELVN stock, giving a Buy rating on May 29. Soumit Roy has given his Buy rati...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/enliven-therapeutics-buy-rating-backed-by-promising-elvn-001-developments-in-cml-treatment-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/enliven-therapeutics-buy-rating-backed-by-promising-elvn-001-developments-in-cml-treatment-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ELVN","LENZ"],"gpt_icon":0},{"id":"2539299970","title":"CFO Benjamin Hohl Reports Disposal of Common Shares of Enliven Therapeutics Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2539299970","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539299970?lang=en_us&edition=fundamental","pubTime":"2025-05-30 05:38","pubTimestamp":1748554735,"startTime":"0","endTime":"0","summary":"Benjamin Hohl, the Chief Financial Officer of Enliven Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 29, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nNDL2WPLQB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"CFO Benjamin Hohl Reports Disposal of Common Shares of Enliven Therapeutics Inc","news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ELVN"],"gpt_icon":0},{"id":"2539059164","title":"Enliven Therapeutics’ ELVN-001: Promising Efficacy and Safety in Late Line CML Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2539059164","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539059164?lang=en_us&edition=fundamental","pubTime":"2025-05-29 02:25","pubTimestamp":1748456714,"startTime":"0","endTime":"0","summary":"JonesTrading analyst Soumit Roy has maintained their bullish stance on ELVN stock, giving a Buy rating on May 15. Soumit Roy has given his Buy rati...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/enliven-therapeutics-elvn-001-promising-efficacy-and-safety-in-late-line-cml-market?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/enliven-therapeutics-elvn-001-promising-efficacy-and-safety-in-late-line-cml-market?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","LENZ","ELVN","BK4139","BK4007"],"gpt_icon":0},{"id":"2537924089","title":"Enliven Therapeutics Inc. to Participate in TD Cowen's 6th Annual Oncology Innovation Summit","url":"https://stock-news.laohu8.com/highlight/detail?id=2537924089","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537924089?lang=en_us&edition=fundamental","pubTime":"2025-05-23 04:05","pubTimestamp":1747944328,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, is set to present at TD Cowen's 6th Annual Oncology Innovation Summit on Tuesday, May 27, 2025. The presentation will take the form of a fireside chat and will offer insights from ASCO & EHA.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via PR Newswire  on May 22, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250522:nNDL5CF2cZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELVN","BK4007"],"gpt_icon":0},{"id":"2537522259","title":"Enliven Therapeutics CEO Samuel Kintz Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2537522259","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537522259?lang=en_us&edition=fundamental","pubTime":"2025-05-22 06:30","pubTimestamp":1747866630,"startTime":"0","endTime":"0","summary":"Samuel Kintz, President and CEO of Enliven Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 21, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250521:nNDLbFrL2R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELVN","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":58,"code":"91000000","status":"200"}]}}